Literature DB >> 17846190

Analysis of metabolic indices in regions of abnormal perfusion in patients with high-grade glioma.

J M Lupo1, S Cha, S M Chang, S J Nelson.   

Abstract

BACKGROUND AND
PURPOSE: MR spectroscopic imaging (MRSI) and dynamic susceptibility-contrast MR imaging (DSC-MR imaging) are functional in vivo techniques for assessing tumor metabolism and vasculature characteristics. Because tumor hypoxia is influenced by tortuous, degraded, swollen, and angiogenic tumor vasculature, regions of abnormal perfusion parameters should coexist with changes in lactate and creatine metabolite levels.
MATERIALS AND METHODS: DSC-MR imaging and lactate-edited MRSI were performed on 38 treatment-naive patients with high-grade gliomas (17 grade III, 21 grade IV) before surgical diagnosis. Regions of abnormal perfusion were determined from peak height and percent recovery maps for each voxel within the spectroscopic imaging volume. Choline, creatine, and lactate levels within voxels experiencing only abnormal peak height (aPH), only abnormal recovery (aRec), and both abnormal peak height and recovery (aPH+aRec) were determined and compared to the surrounding T2 hyperintensity (T2h) and normal-appearing white matter.
RESULTS: There were decreasing trends in volume from aPH to aRec to aPH+aRec regions for both grade III and grade IV gliomas. Grade IV gliomas exhibited significantly elevated choline in all abnormal perfusion regions, with reduced creatine and increased lactate in the aRec region relative to the surrounding T2h. Grade III gliomas showed trends toward increased creatine within the aPH region and reduced levels within the aRec region.
CONCLUSION: Depressed creatine and elevated lactate levels confirmed the lack of oxygenation within regions of compromised vascular integrity. Identification of regions with leaky or dense vasculature and metabolic markers of hypoxia and cellular proliferation could be useful in determining the more aggressive part of the tumor for targeting, monitoring, and assessing effects of treatment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17846190      PMCID: PMC2855720          DOI: 10.3174/ajnr.A0586

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  37 in total

Review 1.  Oxidative metabolism of brain tumors.

Authors:  N Allen
Journal:  Prog Exp Tumor Res       Date:  1972

2.  Metabolism of human gliomas: assessment with H-1 MR spectroscopy and F-18 fluorodeoxyglucose PET.

Authors:  J R Alger; J A Frank; A Bizzi; M J Fulham; B X DeSouza; M O Duhaney; S W Inscoe; J L Black; P C van Zijl; C T Moonen
Journal:  Radiology       Date:  1990-12       Impact factor: 11.105

3.  In vivo imaging of glucose consumption and lactate concentration in human gliomas.

Authors:  K Herholz; W Heindel; P R Luyten; J A denHollander; U Pietrzyk; J Voges; H Kugel; G Friedmann; W D Heiss
Journal:  Ann Neurol       Date:  1992-03       Impact factor: 10.422

4.  Proton MR spectroscopy of intracranial tumours: in vivo and in vitro studies.

Authors:  S S Gill; D G Thomas; N Van Bruggen; D G Gadian; C J Peden; J D Bell; I J Cox; D K Menon; R A Iles; D J Bryant
Journal:  J Comput Assist Tomogr       Date:  1990 Jul-Aug       Impact factor: 1.826

5.  Assessment of cerebral blood volume with dynamic susceptibility contrast enhanced gradient-echo imaging.

Authors:  F Gückel; G Brix; K Rempp; M Deimling; J Röther; M Georgi
Journal:  J Comput Assist Tomogr       Date:  1994 May-Jun       Impact factor: 1.826

Review 6.  Vascular and interstitial barriers to delivery of therapeutic agents in tumors.

Authors:  R K Jain
Journal:  Cancer Metastasis Rev       Date:  1990-11       Impact factor: 9.264

7.  Comparison of cerebral blood volume and vascular permeability from dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade.

Authors:  Meng Law; Stanley Yang; James S Babb; Edmond A Knopp; John G Golfinos; David Zagzag; Glyn Johnson
Journal:  AJNR Am J Neuroradiol       Date:  2004-05       Impact factor: 3.825

8.  Glioblastoma cells release factors that disrupt blood-brain barrier features.

Authors:  Stefan W Schneider; Thomas Ludwig; Lars Tatenhorst; Stephan Braune; Hans Oberleithner; Volker Senner; Werner Paulus
Journal:  Acta Neuropathol       Date:  2004-01-17       Impact factor: 17.088

9.  Analysis of brain tumors using 1H magnetic resonance spectroscopy.

Authors:  D Q McBride; B L Miller; D L Nikas; S Buchthal; L Chang; F Chiang; R A Booth
Journal:  Surg Neurol       Date:  1995-08

10.  Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings.

Authors:  H J Aronen; I E Gazit; D N Louis; B R Buchbinder; F S Pardo; R M Weisskoff; G R Harsh; G R Cosgrove; E F Halpern; F H Hochberg
Journal:  Radiology       Date:  1994-04       Impact factor: 11.105

View more
  11 in total

1.  Stripe-like increase of rCBV beyond the visible border of glioblastomas: site of tumor infiltration growing after neurosurgery.

Authors:  Stella Blasel; Kea Franz; Hanns Ackermann; Stefan Weidauer; Friedhelm Zanella; Elke Hattingen
Journal:  J Neurooncol       Date:  2010-10-07       Impact factor: 4.130

2.  Immediate post-operative MRI suggestive of the site and timing of glioblastoma recurrence after gross total resection: a retrospective longitudinal preliminary study.

Authors:  Thibault Smets; Tévi Morel Lawson; Cécile Grandin; Aleksandar Jankovski; Christian Raftopoulos
Journal:  Eur Radiol       Date:  2013-01-12       Impact factor: 5.315

3.  Proton magnetic resonance spectroscopy predicts survival in children with diffuse intrinsic pontine glioma.

Authors:  Emilie A Steffen-Smith; Joanna H Shih; Sean J Hipp; Robyn Bent; Katherine E Warren
Journal:  J Neurooncol       Date:  2011-05-13       Impact factor: 4.130

Review 4.  Assessment of therapeutic response and treatment planning for brain tumors using metabolic and physiological MRI.

Authors:  Sarah J Nelson
Journal:  NMR Biomed       Date:  2011-04-27       Impact factor: 4.044

Review 5.  Neuronal-astrocyte metabolic interactions: understanding the transition into abnormal astrocytoma metabolism.

Authors:  Dennis A Turner; David Cory Adamson
Journal:  J Neuropathol Exp Neurol       Date:  2011-03       Impact factor: 3.685

6.  Signal intensity in T2' magnetic resonance imaging is related to brain glioma grade.

Authors:  Laura Saitta; Oliver Heese; Ann-Freya Förster; Jakob Matschke; Susanne Siemonsen; Lucio Castellan; Manfred Westphal; Jens Fiehler; Einar Goebell
Journal:  Eur Radiol       Date:  2010-11-11       Impact factor: 5.315

7.  Comparison of DSC-MRI post-processing techniques in predicting microvascular histopathology in patients newly diagnosed with GBM.

Authors:  Emma Essock-Burns; Joanna J Phillips; Annette M Molinaro; Janine M Lupo; Soonmee Cha; Susan M Chang; Sarah J Nelson
Journal:  J Magn Reson Imaging       Date:  2012-12-19       Impact factor: 4.813

8.  MR-based hypoxia measures in human glioma.

Authors:  Vivien Tóth; Annette Förschler; Nuria M Hirsch; Jürgen den Hollander; Hendrik Kooijman; Jens Gempt; Florian Ringel; Jürgen Schlegel; Claus Zimmer; Christine Preibisch
Journal:  J Neurooncol       Date:  2013-08-07       Impact factor: 4.130

Review 9.  Assessing and monitoring intratumor heterogeneity in glioblastoma: how far has multimodal imaging come?

Authors:  Natalie R Boonzaier; Sara G M Piccirillo; Colin Watts; Stephen J Price
Journal:  CNS Oncol       Date:  2015-10-26

10.  Inhibition of Pediatric Glioblastoma Tumor Growth by the Anti-Cancer Agent OKN-007 in Orthotopic Mouse Xenografts.

Authors:  Patricia Coutinho de Souza; Samantha Mallory; Nataliya Smith; Debra Saunders; Xiao-Nan Li; Rene Y McNall-Knapp; Kar-Ming Fung; Rheal A Towner
Journal:  PLoS One       Date:  2015-08-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.